# US 2020/0216907 A1 · Methods for therapeutics prescreening in bodily fluids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0216907 A1
- Document ID: US20200216907A1
- Status: Published application
- Kind: A1
- Application number: 16/628,210
- Filed: 2018-07-05
- Published: 2020-07-09
- Earliest claimed: 2017-07-06
- Assignees: Barcode Diagnostics Ltd.
- Applicants: Barcode Diagnostics Ltd.
- Inventors: Ronen EAVRI; Annie SABBAH; Felix BADINTER; Raphael TSHUVA; Avi SCHROEDER
- Web page: https://patentgrep.com/patent/US20200216907A1

## CPC

- C12Q 1/68: involving nucleic acids
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 49/00: Preparations for testing in vivo
- A61K 49/0017: {Fluorescence in vivo}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/136: Screening for pharmacological compounds
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method for using bodily fluids in determining the cell-specific potency of drugs is provided. A composition comprising a plurality of types of carriers, wherein each carrier comprises a single-cell lethal amount of a therapeutic agent and a unique barcode identifying that agent and wherein the composition comprises equal numbers of each carrier type, equal concentrations of the agent and equal concentrations of each barcode is also provided. Further, methods useful for studying the therapeutic profile of one or more drugs within a cell microenvironment, including but not limited to a tumor, are provided.

## Claims

### Claim 1

A method for predicting the response of a subject afflicted with a disease to at least one therapeutic agent, the method comprising the steps of:
(a) administering to the subject a composition comprising a plurality of types of carriers, each type of carrier independently comprises at least a single-cell lethal amount of at least one therapeutic agent and one or more barcodes uniquely identifying said at least one therapeutic agent;
(b) obtaining a fluid sample from said subject; and
(c) identifying, in said fluid, the efficacy of said at least one therapeutic agent by the presence of said unique barcode;
thereby predicting the response of a subject afflicted with a disease to a therapeutic agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein said composition comprises a substantially equal number of each type of carrier.

### Claim 3 (depends on 1)

The method of claim 1, wherein each type of carrier comprises a substantially equal barcode concentration.

### Claim 4 (depends on 1)

The method of claim 1, wherein each type of carrier comprises a substantially equal concentration of said at least one therapeutic agent relative to an effective therapeutic dose (ETD) of said at least one therapeutic agent.

### Claim 5 (depends on 1)

The method of claim 1, wherein said at least one therapeutic agent is cytotoxic to a cell of said disease.

### Claim 6 (depends on 5)

The method of claim 5, wherein said disease is cancer, and said at least one therapeutic agent is cytotoxic to cancer cells.

### Claim 7 (depends on 1)

The method of claim 1, wherein each type of carrier comprises a different at least one therapeutic agent.

### Claim 8 (depends on 1)

The method of claim 1, wherein said administration is intravenous injection and said composition comprises 1-200 of each type of carrier per a single disease cell of said subject.

### Claim 9 (depends on 1)

The method of claim 1, wherein said administration is intratumoral injection, and said composition comprises 1-20 of each type of carrier per a single disease cell of said subject.

### Claim 10 (depends on 1)

The method of claim 1, wherein said obtaining is performed within a time frame of 48-192 hours following administration of said composition.

### Claim 11 (depends on 1)

The method of claim 1, wherein said barcode is a nucleic acid molecule and said identifying comprises sequencing said nucleic acid molecule, amplifying said nucleic acid molecule, or both.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein said fluid is selected from the group consisting of: blood, plasma, serum, saliva, urine, lymph, tumor fluid, breast milk, cerebral spinal fluid and seminal fluid.

### Claim 14 (depends on 13)

The method of claim 13, wherein said fluid is blood.

### Claim 15 (depends on 1)

The method of claim 1, further comprising before step (a) obtaining a fluid sample from said subject and identifying the percentage of tumor DNA in said sample, and wherein said identifying the efficacy of said at least one therapeutic agent by the unique barcode comprises a comparison to said pre-administration tumor DNA percentage.

### Claim 16 (depends on 1)

The method of claim 1, further comprising removing intact cells from said fluid sample before step (c).

### Claim 17 (depends on 1)

The method of claim 1, further comprising removing intact carrier from said fluid sample before step (c).

### Claim 18 (depends on 1)

The method of claim 1, wherein said at least one carrier further comprises a tag.

### Claim 19 (depends on 1)

The method of claim 1, wherein said unique barcode comprises a cleavage site specific to a nuclease specific to a cell of said disease.

### Claim 20 (depends on 1)

The method of claim 1, wherein said unique barcode comprises a cleavage site specific to a nuclease with increased cytoplasmic localization in a cell of said disease.

### Claim 21 (depends on 1)

The method of claim 1, wherein said single-cell lethal amount is between 0.1% and 3% of the ETD.
